Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART: Physician Education for Regorafenib in mCRC
NCT02287025Phase 4Terminated
- Sponsor
- Bayer
- Start
- Nov 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of regorafenib in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Bayer. Primary endpoint: Proportion of Patients Who Discontinue Prior to Documented Progression of Disease (PD) or Death at 1 year. Started Nov 2014; status: terminated.
02
Drugs
regorafenib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02287025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287025.